Yifan Zhai

This inventor holds 22 USPTO granted patents and 21 published patent applications, plus 4 CIPO patents and 13 EPO patents. Top assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited, Ascentage Pharma (Suzhou) Co., Ltd.. Active years: 2022-2026.

USPTO Granted Patents = 22 (Patent Applications = 21)

% Patents Active = 86.4

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 24)

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

18 out of 31

Ascentage Pharma (Suzhou) Co., Ltd.

patents

12 out of 29

Ascentage Pharma Group Corp Limited

patents

4 out of 10

Ascentage Pharma (Suzhou) Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2022-2026

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12746221 - Combinations of Bcl-2/Bcl-xL inhibitors and related uses (2026-09-29),

2. 12728113 - Microsuspension of an MDM2 inhibitor and therapeutic applications thereof (2026-09-08),

3. 12648945 - Compositions and methods for treating systemic lupus erythematosus (2026-06-09),

4. 12544370 - Methods for cancer therapy (2026-02-10),

5. 12514863 - Pharmaceutical combination and use thereof (2026-01-06),

6. 12370197 - Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases (2025-07-29),

7. 12343352 - N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors (2025-07-01),

8. 12287338 - Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway (2025-04-29),

9. 12268665 - Combination of immunotherapies with MDM2 inhibitors (2025-04-08),

10. 12233047 - Pharmaceutical combination and use thereof (2025-02-25),

11. 12194024 - Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease (2025-01-14),

12. 12186304 - Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule (2025-01-07),

13. 12083136 - Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof (2024-09-10),

14. 11850239 - MDM2 inhibitor and a platinum compound for cancer treatment (2023-12-26),

15. 11554127 - Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP (2023-01-17),

Title: Yifan Zhai: Innovator in Cancer Treatment

Introduction

Yifan Zhai is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of cancer treatment. With a total of 22 patents to his name, Zhai has focused on developing innovative therapies that target hematological malignancies.

Latest Patents

Among his latest patents is a combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent. This invention provides a method for the prevention and treatment of diseases, particularly cancer. The combination product includes a Bcl-2/Bcl-xL inhibitor of formula (I-A) and homoharringtonine or an active derivative thereof. This combination is designed for the preparation of a medicament aimed at treating hematological malignancies. Another notable patent involves N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors, which outlines methods for treating hematologic malignancies through a step-wise dosing regimen.

Career Highlights

Yifan Zhai has worked with Ascentage Pharma, a leading company in the biopharmaceutical sector. His role at Ascentage Pharma (Suzhou) Co., Ltd. and Ascentage Pharma Group Corp Limited has allowed him to contribute to groundbreaking research and development in cancer therapies.

Collaborations

Zhai has collaborated with notable professionals in his field, including Dajun Yang and Douglas Dong Fang. These partnerships have further enhanced his research and innovation efforts.

Conclusion

Yifan Zhai's work in developing innovative cancer treatments showcases his dedication to improving patient outcomes. His patents reflect a commitment to advancing medical science and providing new hope for those affected by hematological malignancies.